Chioma Izzi-Engbeaya (0000-0001-7599-0166)

Personal information

No personal information available

Biography

Dr Chioma Izzi-Engbeaya is a Clinical Academic in the Section of Endocrinology and Investigative Medicine and a Consultant Endocrinologist at Imperial College Healthcare NHS Trust. Her research and clinical interests include assessing the hormonal interactions between metabolic and reproductive systems, as well as investigating the management of obesity and obesity-related co-morbidities.

Dr Izzi-Engbeaya completed her undergraduate medical training at Guy’s Kings and St Thomas’ Medical School in 2004. During this time she also completed an Intercalated BSc in Endocrinology. Her junior doctor training posts were undertaken at various London NHS Trusts including Guy’s and St Thomas’ NHS Trust and Imperial College Healthcare NHS Trust. She became an NIHR Academic Clinical Fellow during her training as a Diabetes and Endocrinology Registrar and was subsequently awarded a 1-year Imperial Health Charity Fellowship, followed by an MRC Clinical Research Training PhD Fellowship in 2014. She completed her PhD (investigating the neuroendocrine control of metabolism and reproduction) with Professor Waljit Dhillo and Dr James Gardiner in 2018. In 2019, she was awarded an Imperial College-BRC funded IPPRF Clinical Research Fellowship, during which she investigated the impact of reproductive hormones on metabolic conditions. In 2024, she was awarded an NIHR Senior Clinical and Practitioner Research Award, and continues to undertake translational and clinical research.

Alongside her research and clinical work, Dr Izzi-Engbeaya is actively involved in education and training. In 2020, she was appointed the Academic Lead for the Implementation of the BMA Charter, and from 2021-2024 she was the Director of Equality, Diversity and Inclusivity in Imperial College School of Medicine. In addition, Dr Izzi-Engbeaya is the Pathway Director of the Pharmacology Intercalated BSc (Imperial College School of Medicine) and the Deputy Director of the Clinical Academic Training Office (Imperial College Academic Health Science Centre).

Activities

Collapse all

Items per page:

Page 1 of 2

Commentary: ‘Diversity of invited speakers at endocrinology conferences’

Clinical Endocrinology

2024-01 | Journal article

DOI: 10.1111/cen.14656

Contributors: Chioma Izzi‐Engbeaya; Victoria Salem

Chioma Izzi-Engbeaya

https://orcid.org/0000-0001-7599-0166

Personal information

Biography

Activities

Works (50 of 53)

Commentary: ‘Diversity of invited speakers at endocrinology conferences’

Brown adipose tissue and regulation of human body weight

Insulin-like peptide 3 (INSL3) in congenital hypogonadotrophic hypogonadism (CHH) in boys with delayed puberty and adult men.

The acute effect of glucagon on components of energy balance and glucose homoeostasis in adults without diabetes: a systematic review and meta-analysis.

Gut hormones and reproduction

Letter to the editor of clinical endocrinology: Assessment of adrenal function in patients who survive COVID-19.

Targeting hepatic kisspeptin receptor ameliorates nonalcoholic fatty liver disease in a mouse model.

The benefit of dexamethasone in patients with COVID-19 infection is preserved in patients with diabetes.

Emerging roles for kisspeptin in metabolism

Preserved C‐peptide in survivors of COVID‐19: Post hoc analysis

Changes in Circulating Kisspeptin Levels During Each Trimester in Women With Antenatal Complications

Normal Adrenal and Thyroid Function in Patients Who Survive COVID-19 Infection

Performance of plasma kisspeptin as a biomarker for miscarriage improves with gestational age during the first trimester.

Adverse outcomes in COVID-19 and diabetes: a retrospective cohort study from three London teaching hospitals

Representing the Metabolome with High Fidelity: Range and Response as Quality Control Factors in LC-MS-Based Global Profiling.

Functions of galanin, spexin and kisspeptin in metabolism, mood and behaviour.

Kisspeptin-54 Accurately Identifies Hypothalamic Gonadotropin-Releasing Hormone Neuronal Dysfunction in Men with Congenital Hypogonadotropic Hypogonadism.

Kisspeptin receptor agonist has therapeutic potential for female reproductive disorders

Endocrine Requirements for Oocyte Maturation Following hCG, GnRH Agonist, and Kisspeptin During IVF Treatment.

Using Aptamers as a Novel Method for Determining GnRH/LH Pulsatility

Severe COVID-19 and Diabetes - A Retrospective Cohort Study from Three London Teaching Hospitals

Acute Effects of Glucagon on Reproductive Hormone Secretion in Healthy Men

OR20-06 Kisspeptin as a Biomarker for Pregnancy Complications

Pharmacodynamic Response to Anti-thyroid Drugs in Graves' Hyperthyroidism.

Glucose in the hypothalamic paraventricular nucleus regulates GLP-1 release

Effects of Glucagon-like Peptide-1 on the Reproductive Axis in Healthy Men

Effects of corticosterone within the hypothalamic arcuate nucleus on food intake and body weight in male rats

Effects of Peptide YY on the Hypothalamic-Pituitary-Gonadal Axis in Healthy Men

Kisspeptin and Glucose Homeostasis.

OR32-3 Kisspeptin- a Novel Clinical Test of Hypothalamic Function in Men with Hypogonadotrophic Hypogonadism

OR33-4 A Single Subcutaneous Injection Of The Kisspeptin Analogue, MVT-602, Induces A More Prolonged LH Surge Compared With Kisspeptin-54 In Healthy Women

SUN-112 Arcuate 11-Betahydroxysteroid Dehydrogenase Type1 Regulates Energy Homeostasis

SUN-LB044 Effects of Glucagon-Like Peptide-1 (GLP-1) on the Hypothalamic-Pituitary-Gonadal Axis in Healthy Men

The effects of kisspeptin on β‐cell function, serum metabolites and appetite in humans

Modulations of human resting brain connectivity by kisspeptin enhance sexual and emotional functions

Hypothalamic arcuate nucleus glucokinase regulates insulin secretion and glucose homeostasis

Hypothalamic Response to Kisspeptin-54 and Pituitary Response to Gonadotropin-Releasing Hormone Are Preserved in Healthy Older Men.

Reply: Clinical trial registry alone is not adequate: on the perception of possible endpoint switching and P-hacking.

A second dose of kisspeptin-54 improves oocyte maturation in women at high risk of ovarian hyperstimulation syndrome: a Phase 2 randomized controlled trial.

Thermal Imaging Is a Noninvasive Alternative to PET/CT for Measurement of Brown Adipose Tissue Activity in Humans.

Kisspeptin modulates sexual and emotional brain processing in humans.

Novel circulating placental markers prokineticin-1, soluble fms-like tyrosine kinase-1, soluble endoglin and placental growth factor and association with late miscarriage.

Glucagon increases energy expenditure independently of brown adipose tissue activation in humans.

Efficacy of Kisspeptin-54 to Trigger Oocyte Maturation in Women at High Risk of Ovarian Hyperstimulation Syndrome (OHSS) During In Vitro Fertilization (IVF) Therapy.

Neurokinin B administration induces hot flushes in women.

Associations of coefficient of variation of serum GH with previous radiotherapy, hypopituitarism and cardiac disease in patients with treated acromegaly.

Reduced levels of plasma kisspeptin during the antenatal booking visit are associated with increased risk of miscarriage.

Insights into Brown Adipose Tissue Physiology as Revealed by Imaging Studies.

Kisspeptin-54 triggers egg maturation in women undergoing in vitro fertilization.

Kisspeptin is providing new insights into the control of reproduction.